Cross-Sector entity
Thomas Willkan is most often covered alongside FulcrumSec, which appears in 4 of these 4 stories. Coverage clusters in ai-research, which accounts for 1 of those 4, with the remainder spread across 3 other categories. Each carries 2 original sources on average.
4 verified stories tracked
Last mentioned: Jun 17, 2026
Entity pulse
Coverage balance Negative coverage leads. Negative coverage exceeds positive coverage by 100 percentage points.
Figures are computed live from our source-verified story record — see our methodology for how impact and sentiment are derived.
Thomas Willkan is most often covered alongside FulcrumSec, which appears in 4 of these 4 stories. Coverage clusters in ai-research, which accounts for 1 of those 4, with the remainder spread across 3 other categories. Each carries 2 original sources on average. We currently track 4 Cross-Sector stories that mention Thomas Willkan, all published on June 17, 2026.
Computed from the 4 stories linked to this entity. Beat comparisons are omitted because no baseline was available for this window.
Coverage cohort
Other entities that clear the same relevance threshold in stories also covering Thomas Willkan. Shared-story counts are live from our verified record — not editorial picks.
FulcrumSec Goes Public
FulcrumSec posts a lengthy message on its website detailing the breach, the $25 million extortion demand, and the decision to explore private data sales after payment refusal.
Company Discloses Breach
Novo Nordisk publicly announces a cybersecurity incident involving unauthorized access to a limited number of internal IT systems and some personal data.
Novo Nordisk Responds
Roughly 48 hours after initial outreach, Novo Nordisk uses a Proton Mail address to verify the legitimacy of the claim by requesting specific file contents.
Initial Extortion Contact
FulcrumSec contacts unnamed Novo Nordisk executives demanding $25 million; the exact method is not publicly detailed.
FulcrumSec Emerges
The cyber extortion group FulcrumSec first appears, later becoming known for credible claims and sophisticated intrusions.
A cyber extortion group claims to have stolen over a terabyte of data from pharmaceutical giant Novo Nordisk, including clinical trial data of 11,500 patients. While some sensitive data is being withheld, the breach highlights critical vulnerabilities in healthcare data security and could trigger regulatory scrutiny under GDPR and other frameworks.
Cybersecurity experts assess FulcrumSec as a serious threat actor, and its two-month dwell time inside Novo Nordisk before making a $25 million extortion demand reflects advanced persistent threat tactics. The breach highlights growing risks to critical infrastructure and the evolution of cyber extortion with a harm-reduction narrative.
FulcrumSec's breach of Novo Nordisk could jeopardize years of R&D as stolen data includes proprietary information on released and unreleased drugs, trial data, and manufacturing processes. With the extortion failure and potential data sale, rival pharma firms may gain competitive intelligence, threatening Novo's market position.
The FulcrumSec breach exposed Novo Nordisk’s internal AI model information alongside drug data, potentially compromising years of machine learning work used in drug discovery. The theft of proprietary AI assets highlights escalating cyber risks for AI-driven pharma innovation.
Source: Straitstimes · Times of News (in)
